# Health Catalyst, Inc.: overview

HCAT · Nasdaq · CIK 1636422 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/hcat.md) · [Financials](/companies/hcat/financials.md) · [Filings](/companies/hcat/filings.md) · [Insiders](/companies/hcat/insiders.md)

Latest reported revenue: [$70.5m](/filings/0001636422-26-000097.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001636422-26-000097).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [76.4](/filings/0001636422-25-000146.md) | [79.6 d](/filings/0001636422-26-000035.md) | [79.4](/filings/0001636422-26-000066.md) | [80.7](/filings/0001636422-26-000097.md) | [76.3](/filings/0001636422-25-000146.md) | [74.7 d](/filings/0001636422-26-000035.md) | [70.8](/filings/0001636422-26-000066.md) | [70.5](/filings/0001636422-26-000097.md) |
| Gross margin | % | [47.5%](/filings/0001636422-25-000146.md) | not reported | not reported | not reported | [52.6%](/filings/0001636422-25-000146.md) | not reported | not reported | not reported |
| Operating margin | % | [(17.9%)](/filings/0001636422-25-000146.md) | [(22.0%) d](/filings/0001636422-26-000035.md) | [(25.4%)](/filings/0001636422-26-000066.md) | [(46.0%)](/filings/0001636422-26-000097.md) | [(22.9%)](/filings/0001636422-25-000146.md) | [(115.3%) d](/filings/0001636422-26-000035.md) | [(150.5%)](/filings/0001636422-26-000066.md) | [(51.8%)](/filings/0001636422-26-000097.md) |
| Net margin | % | [(19.3%)](/filings/0001636422-25-000146.md) | [(26.0%) d](/filings/0001636422-26-000035.md) | [(29.9%)](/filings/0001636422-26-000066.md) | [(50.8%)](/filings/0001636422-26-000097.md) | [(29.1%)](/filings/0001636422-25-000146.md) | [(121.9%) d](/filings/0001636422-26-000035.md) | [(156.9%)](/filings/0001636422-26-000066.md) | [(57.5%)](/filings/0001636422-26-000097.md) |
| Diluted EPS | $ per share | [(0.24)](/filings/0001636422-25-000146.md) | not reported | [(0.35)](/filings/0001636422-26-000066.md) | [(0.59)](/filings/0001636422-26-000097.md) | [(0.32)](/filings/0001636422-25-000146.md) | not reported | [(1.53)](/filings/0001636422-26-000066.md) | [(0.55)](/filings/0001636422-26-000097.md) |
| Free cash flow | $m | [5.5 d](/filings/0001636422-25-000146.md) | [(3.9) d](/filings/0001636422-26-000035.md) | [(0.4)](/filings/0001636422-26-000066.md) | [(9.2) d](/filings/0001636422-26-000097.md) | [(0.7) d](/filings/0001636422-25-000146.md) | [9.6 d](/filings/0001636422-26-000035.md) | [18.2](/filings/0001636422-26-000066.md) | [(0.1) d](/filings/0001636422-26-000097.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [242](/filings/0001636422-24-000016.md) | [276](/filings/0001636422-25-000028.md) | [296](/filings/0001636422-26-000035.md) | [307](/filings/0001636422-26-000035.md) | [311](/filings/0001636422-26-000035.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(59.4%)](/filings/0001636422-24-000016.md) | [(50.7%)](/filings/0001636422-25-000028.md) | [(42.9%)](/filings/0001636422-26-000035.md) | [(22.8%)](/filings/0001636422-26-000035.md) | [(51.7%)](/filings/0001636422-26-000035.md) |
| Net margin | % | [(63.3%)](/filings/0001636422-24-000016.md) | [(49.7%)](/filings/0001636422-25-000028.md) | [(39.9%)](/filings/0001636422-26-000035.md) | [(22.7%)](/filings/0001636422-26-000035.md) | [(57.2%)](/filings/0001636422-26-000035.md) |
| Diluted EPS | $ per share | [(3.23)](/filings/0001636422-24-000016.md) | [(2.63)](/filings/0001636422-25-000028.md) | [(2.09)](/filings/0001636422-26-000035.md) | [(1.15)](/filings/0001636422-26-000035.md) | [(2.55)](/filings/0001636422-26-000035.md) |
| Free cash flow | $m | [(33.6)](/filings/0001636422-24-000016.md) | [(37.4)](/filings/0001636422-25-000028.md) | [(34.3)](/filings/0001636422-26-000035.md) | [12.9](/filings/0001636422-26-000035.md) | [(0.2)](/filings/0001636422-26-000035.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/hcat/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [First Light Asset Management, LLC](/funds/1600004.md) | 2026-06-30 | $25.5m | 12,810,861 |  | Reduced −67,839 |
| [CDC Financial, Inc.](/funds/2077836.md) | 2026-06-30 | $14.1m | 7,092,698 |  | Added +785,644 |
| [Palogic Value Management, L.P.](/funds/1532943.md) | 2026-06-30 | $9.8m | 4,922,442 |  | Added +2,025,842 |
| [Impax Asset Management Group plc](/funds/1749768.md) | 2026-06-30 | $8.0m | 4,000,000 |  | Added +1,250,000 |
| [Nepsis Inc.](/funds/1587643.md) | 2026-06-30 | $5.9m | 2,976,187 |  | Added +1,099,898 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $5.9m | 2,971,598 |  | Added +85,945 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $3.7m | 1,836,373 |  | Reduced −3,301,649 |
| [Whetstone Capital Advisors, LLC](/funds/1607278.md) | 2026-06-30 | $3.0m | 1,515,000 | Call | Unchanged |
| [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $2.1m | 1,037,782 |  | Added +1,011,214 |
| [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $1.8m | 911,819 |  | Reduced −323,051 |

## Recent filings

[All 931 filings](/companies/hcat/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-14 | 20:25 ET | [8-K](/filings/0001636422-26-000111.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001636422-26-000111 |
| 2026-09-08 | 21:04 ET | [SCHEDULE 13D/A](/filings/0001104659-26-105948.md) | Ownership report, active investor, amended | 0001104659-26-105948 |
| 2026-09-08 | 12:13 ET | [8-K](/filings/0001636422-26-000104.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001636422-26-000104 |
| 2026-08-06 | 20:58 ET | [10-Q](/filings/0001636422-26-000097.md) | Quarterly report, period 2026-06-30 | 0001636422-26-000097 |
| 2026-08-06 | 20:09 ET | [8-K](/filings/0001636422-26-000091.md) | 1.02 Termination of a material agreement; 2.01 Completion of an acquisition or disposition; 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001636422-26-000091 |
| 2026-07-20 | 22:40 ET | [8-K](/filings/0001636422-26-000085.md) | 5.07 Shareholder vote results | 0001636422-26-000085 |
| 2026-06-22 | 19:55 ET | [SCHEDULE 13D](/filings/0001104659-26-076342.md) | Ownership report, active investor | 0001104659-26-076342 |
| 2026-06-08 | 23:12 ET | [SCHEDULE 13D/A](/filings/0001607278-26-000004.md) | Ownership report, active investor, amended | 0001607278-26-000004 |
| 2026-06-04 | 13:10 ET | [8-K](/filings/0001636422-26-000082.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001636422-26-000082 |
| 2026-06-03 | 20:11 ET | [DEF 14A](/filings/0001636422-26-000075.md) | Proxy statement, period 2025-12-31 | 0001636422-26-000075 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001636422-26-000035.md), filed Mar 12, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/85cc9323-e16e-41f1-8128-736f9da000c9)

## About the filer

- CIK: 1636422
- Tickers: HCAT
- Exchange: Nasdaq
- SIC code: 7370 Services-Computer Programming, Data Processing, Etc.
- State of incorporation: DE
- Filer category: Accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.